Omnicell (OMCL) Misses Q4 EPS by 1c, Revenues Beat; Offers FY20 EPS Mid-Point Guidance Above Consensus, FY20 Revenue Views Above Consensus

Omnicell (NASDAQ: OMCL) reported Q4 EPS of $0.77, $0.01 worse than the analyst estimate of $0.78. Revenue for the quarter came in at $248.3 million versus the consensus estimate of $243.69 million.

Non-GAAP Results

• Non-GAAP revenues for the fourth quarter of 2019 were $248.3 million, up $36.5 million, or 17% from the fourth quarter of 2018. Non-GAAP revenues for the year ended December 31, 2019 were $897.0 million, up $109.7 million, or 14% from the year ended December 31, 2018.
• Non-GAAP net income for the fourth quarter of 2019 was $33.5 million, or $0.77 per diluted share. This compares to non-GAAP net income of $29.1 million, or $0.70 per diluted share, for the fourth quarter of 2018.
• Non-GAAP net income for the year ended December 31, 2019 was $120.7 million, or $2.81 per diluted share. This compares to non-GAAP net income of $84.6 million, or $2.09 per diluted share for the year ended December 31, 2018.

Total product bookings for the year ended December 31, 2019 were $813 million compared to $716 million for the year ended December 31, 2018. Total product backlog for the year ended December 31, 2019 was $588 million compared to $478 million for the year ended December 31, 2018, or an increase of 23% year over year.

“We believe the strong growth in our business over the past year is a testament that the vision of the autonomous pharmacy is resonating with our customers,” said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. “I am excited to see the strides we are making to advance this vision and the way we are helping to improve medication management by driving toward a zero-error, fully automated and digitized infrastructure across the continuum of care.”

GUIDANCE:

Omnicell sees Q1 2020 EPS of $0.52-$0.57, versus the consensus of $0.57. Omnicell sees Q1 2020 revenue of $221-227 million, versus the consensus of $225.43 million.

Omnicell sees FY2020 EPS of $2.96-$3.16, versus the consensus of $3.01. Omnicell sees FY2020 revenue of $1-1.02 billion, versus the consensus of $0.991 billion.

• For the first quarter of 2020, the Company expects non-GAAP total revenues to be between $221 million and $227 million. The Company expects non-GAAP product revenues to be between $163 million and $168 million, and non-GAAP service revenues to be between $58 million and $59 million. The Company expects first quarter 2020 non-GAAP earnings to be between $0.52 and $0.57 per share.
• For the full year 2020, the Company expects product bookings to be between $865 million and $900 million. The Company expects non-GAAP total revenues to be between $1 billion and $1.02 billion. The Company expects non-GAAP product revenues to be between $752 million and $768 million, and non-GAAP service revenues to be between $248 million and $252 million. The Company expects 2020 non-GAAP earnings to be between $2.96 and $3.16 per share.

For earnings history and earnings-related data on Omnicell (OMCL) click here.

You May Also Be Interested In

• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• MGE Energy VP of energy operations to retire at year-end
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance